Phase 4Completed

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (REALIZE-K)

Phase IV, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Trial Evaluating Sodium Zirconium Cyclosilicate (SZC) for the Management of Hyperkalaemia in Patients With Symptomatic Heart Failure With Reduced Ejection Fraction and Receiving Spironolactone

Sponsor
AstraZeneca (Industry)
Enrollment
366 enrolled
Conditions
Hyperkalaemia; Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate; Placebo; Spironolactone
Ages
adults, older adults
Registry
NCT04676646, EUCTR2020-003312-27

Full record on ClinicalTrials.gov

From the registry

The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).

Primary outcomes

  • Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for Hyperkalaemia

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered